
Dastila 50 Tablet
Marketer
Sun Pharmaceutical Industries Ltd
Salt Composition
Dasatinib (50mg)
Overview Dastila 50 Tablet
Chronic myeloid leukemia (CML) patients whose condition is unresponsive to, or intolerant of, other treatments may find relief with Dastila 50mg tablets. Administer this medication consistently, at the same time each day, with or without food, for optimal efficacy. Dosage and frequency are determined by your physician based on your individual needs and may be adjusted over time; adhere strictly to the prescribed regimen. Incorrect usage or overdosage can lead to severe complications. While therapeutic effects might not be immediately apparent (weeks or months), discontinue only upon your doctor's instruction. Common side effects include nausea, vomiting, abdominal pain, and skin rashes. Increased heart rate, and abnormally high or low blood pressure are less frequent but require immediate medical attention. Regular blood pressure monitoring may be necessary. Avoid antacids within two hours of ingestion. Dastila 50mg can lower blood cell counts, increasing infection risk; regular blood tests are crucial. Inform your healthcare provider of all concurrent medications, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding. Refrain from driving if dizziness or visual disturbances occur.
Uses of Dastila 50 Tablet
Chronic myelogenous leukemia, a type of blood malignancy
Major Benefits of Dastila 50 Tablet:
Administer this medication precisely as your physician directs, adhering to the prescribed dosage and schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Dastila 50 Tablets can be consumed with or without food, though consistent timing is recommended.
Common Side effects of Dastila 50 Tablet:
- Abdominal pain
- Anemia (low number of red blood cells)
- Breathing problems
- Fatigue
- Fever
- Headache
- Infection
- Low blood platelets
- Musculoskeletal (bone, muscle or joint) pain
- Nausea
- Rash
- Vomiting
How to use Dastila 50 Tablet:
Consume this medication according to your physician's prescribed dosage and schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Dastila 50 Tablet can be administered with or without food, however, consistent timing is recommended.
How Dastila 50 Tablet works:
Oncaspar 50mg tablets are a cancer treatment. Their mechanism involves inhibiting the activity of a faulty protein responsible for stimulating cancerous cell proliferation. This action contributes to halting or slowing cancer progression.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Dastila 50 Tablet may be unsafe; physician consultation is advised.
PregnancyCONSULT YOUR DOCTOR
Using Dastila 50 Tablet during pregnancy poses a confirmed risk to the fetus. Its use should be avoided except in potentially life-threatening circumstances where a physician deems the potential benefits outweigh the known hazards. Always seek medical advice before taking this medication.
Breast feedingUNSAFE
Breastfeeding mothers should avoid Dastila 50 Tablets. Evidence indicates potential infant harm from this medication.
DrivingUNSAFE
Driving ability may be impaired by Dastila 50 Tablet side effects. Exercise caution while driving if you experience dizziness or blurred vision after taking Dastila 50 Tablet.
KidneySAFE IF PRESCRIBED
Use of Dastila 50 Tablet in patients with kidney impairment appears to present a low risk. Existing evidence indicates dose modification may be unnecessary, however, physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Dastila 50 Tablet poses no safety concerns for patients with hepatic impairment; dosage modification is unnecessary.
What if you forget to take Dastila 50 Tablet :
Omit any missed Dastila 50 Tablet dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Dastila 50 Tablet
| Label | Value |
|---|---|
| Chemical Type | Pyrimidine and Thiazole Derivatives |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Actions | TKIs |
